Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average): 2013-2024

Historic Shares Outstanding (Weighted Average) for Agios Pharmaceuticals (AGIO) over the last 12 years, with Dec 2024 value amounting to $57.0 million.

  • Agios Pharmaceuticals' Shares Outstanding (Weighted Average) rose 2.12% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year increase of 2.12%. This contributed to the annual value of $57.0 million for FY2024, which is 2.04% up from last year.
  • Agios Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $57.0 million in FY2024, which was up 2.04% from $55.9 million recorded in FY2023.
  • Agios Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $69.3 million during FY2020, with a 5-year trough of $54.3 million in FY2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $56.0 million, with a median of $55.9 million in 2023.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) dropped by 21.59% in 2021, and later increased by 2.04% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $69.3 million in 2020, then dropped by 21.59% to $54.3 million in 2021, then grew by 1.17% to $54.9 million in 2022, then rose by 1.72% to $55.9 million in 2023, then rose by 2.04% to $57.0 million in 2024.